Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in lewy body diseases: Complementary or alternative techniques?

Journal of Neuroimaging

Volumn 24, Issue 2, 2014, Pages 149-154

  Treglia, Giorgio ^a   Cason, Ernesto ^b   Cortelli, Pietro ^c   Gabellini, Anna ^b   Liguori, Rocco ^c   Bagnato, Antonio ^d   Giordano, Alessandro ^a   Fagioli, Giorgio ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Azienda Ospedaliera   (Italy)

Author keywords

Dementia with Lewy bodies; Ioflupane; Lewy body disease; Metaiodobenzylguanidine; Nuclear medicine; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; IOFLUPANE I 123; POTASSIUM PERCHLORATE; (3 IODOBENZYL)GUANIDINE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CARDIAC IMAGING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; FEMALE; HEART SCINTISCANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PARKINSON DISEASE; PARKINSONISM; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERY ELDERLY; COMPARATIVE STUDY; DIAGNOSTIC USE; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84896699978     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2012.00774.x     Document Type: Article

References (28)

1. Hishikawa N, Hashizume Y, Yoshida M, et al. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 2003;105:341-350.
2. Vekrellis K, Xilouri M, Emmanouilidou E, et al. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 2011;10:1015-1025.
3. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol 2000;247(Suppl 2):II3-10.
4. Goldstein DS, Holmes C, Sewell L, et al. Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. Clin Auton Res 2012;22:57-61.
5. Goldstein DS, Orimo S. Cardiac sympathetic neuroimaging: summary of the First International Symposium. Clin Auton Res 2009;19:137-148.
6. Treglia G, Stefanelli A, Cason E, et al. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg 2011;113:823-829.
7. Treglia G, Cason E, Stefanelli A, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res 2012;22:43-55.
8. 23I-MIBG cardiac scintigraphy in Lewy body-related disorders. Mov Disord 2011;26(10):1949-1950.
9. Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging 2012;22:111-117.
10. Treglia G, Cason E, Gabellini A, et al. Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases. Neurol Sci 2010;31:417-422.
11. Isaias IU, Antonini A. Single-photon emission computed tomography in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis 2010;7:319-329.
12. Walker Z, Rodda J. Dopaminergic imaging: clinical utility now and in the future. Int Psychogeriatr 2011;23(Suppl 2):S32-S40.
13. Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010;81:5-12.
14. Stoessl AJ, Martin WW, McKeown MJ, et al. Advances in imaging in Parkinson's disease. Lancet Neurol 2011;10:987-1001.
15. Brooks DJ. Imaging dopamine transporters in Parkinson's disease. Biomark Med 2010;4:651-660.
16. Papathanasiou ND, Boutsiadis A, Dickson J, et al. Diagnostic accuracy of (123)I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 2012;18:225-229.
17. Flotats A, Carrió I, Agostini D, et al; EANM Cardiovascular Committee; European Council of Nuclear Cardiology. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37:1802-1812.
18. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010;37:443-450.
19. Südmeyer M, Antke C, Zizek T, et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med 2011;52:733-740.
20. Novellino F, Arabia G, Bagnato A, et al. Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors. Mov Disord 2009;24:2242-2248.
21. Spiegel J, Hellwig D, Jost WH, et al. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson's disease. Open Neurol J 2007;1:1-4.
22. Spiegel J, Möllers MO, Jost WH, et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 2005;20:552-561.
23. Ishibashi K, Saito Y, Murayama S, et al. Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 2010;37:3-11.
24. Raffel DM, Koeppe RA, Little R, et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes.J Nucl Med 2006;47:1769-1777.
25. Camacho V, Marquié M, Lleó A, et al. Cardiac sympathetic impairment parallels nigrostriatal degeneration in Probable Dementia with Lewy Bodies. Q J Nucl Med Mol Imaging 2011;55:476-483.
26. Marquié Sayagués M, Da Silva Alves L, Molina-Porcel L, et al. (123)I-MIBG myocardial scintigraphy in the diagnosis of Lewy body dementia. Neurologia 2010;25:414-421.
27. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
28. Tateno M, Kobayashi S, Saito T. Imaging improves diagnosis of dementia with Lewy bodies. Psychiatry Invest 2009;6:233-240.